Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
EGFR-mutated lung cancer
Biotech
ArriVent’s phase 3 lung cancer trial flops, sinking stock
A phase 3 lung cancer study of ArriVent BioPharma’s EGFR inhibitor has missed its primary endpoint, sending the biotech’s stock down 57%.
Nick Paul Taylor
Oct 6, 2026 10:51am
Rare EGFR mutation increases lung cancer risk more than smoking
Sep 17, 2026 2:00pm
Cullinan, Taiho tout 6-month survival benefit in lung cancer
Sep 13, 2026 9:45pm
Taiho and Cullinan secure lung cancer victory to challenge J&J
Aug 13, 2026 6:00am
BlossomHill eyes $112M IPO harvest to fund Tagrisso challenger
Aug 3, 2026 9:18am
BlossomHill eyes IPO to grow taller in crowded cancer fields
Jul 17, 2026 12:08pm
